Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate

(Stribild®)

Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate

Drug updated on 11/9/2023

Dosage FormTablet (oral; elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: 150mg/150 mg/200 mg/300 mg)
Drug ClassAntivirals
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Stribild.